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counts immediate post-transplant period. Despite higher
rates in acute and chronic GVHD with FluTBI, overall out-
comes after HCT are comparable to non-TBI containing NMA
regimens for lymphoma.355
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Patients with class 3 thalassemia with high-risk features for
adverse events after high-dose chemotherapy with he-
matopoietic stem cell transplantation (HSCT) are difﬁcult to
treat, tending to either suffer serious toxicity or fail to
establish stable graft function. We performed HSCT in 21
such patients age 7 years and hepatomegaly using a novel
approach with pretransplant immunosuppression followed
by a myeloablative reduced-toxicity conditioning regimen
(ﬂudarabine and i.v. busulfan [Flu-IV Bu]) and then HSCT. The
median patient age was 15 years (range, 10 to 20 years).
Before the Flu-IV Bu + antithymocyte globulin conditioning
regimen, all patients received 1 to 2 cycles of pretransplant
immunosuppression with ﬂudarabine and dexamethasone.
Fifteen patients received a related donor graft, and 6 received
an unrelated donor graft. An initial prompt engraftment of
donor cells with full donor chimerismwas observed in all 18
patients, but 2 patients developed secondary mixed chime-
rism that necessitated withdrawal of immunosuppression to
achieve full donor chimerism. Three patients (14%) had acute
grade III-IV graft-versus-host disease, and 5 patients had
limited chronic graft-versus-host disease. The only treat-
ment-related mortality was from infection, and with a me-
dian follow-up of 50 months (range, 4 to 83), the 5-year
overall survival and thalassemia-free survival were 93%. We
conclude that this novel sequential immunoablative pre-
transplantation conditioning program is safe and effective
for patients with high-risk class 3 thalassemia exhibiting
additional comorbidities.356
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Wiskott-Aldrich syndrome (WAS) is an X-linked immuno-
deﬁciency presented with eczema, microthrombocytopenia,
autoimmune disorders, recurrent infections, and subsequent
malignancies. Little is known on late complications following
hematopoietic stem cell transplant (HSCT) in this population.
In a single-institutional retrospective study of 17 WAS pa-
tients who underwent HSCT between January 1992 andDecember 2012, we evaluated autoimmune manifestations,
serious infections, and graft-versus-host disease (GVHD).
Median age at HSCT was 2.17 years (range 0.28-12.38). Nine
(52.9%) and eight patients (47.1%) received bone marrow and
umbilical cord blood, respectively. Fourteen patients (82.3%)
underwent HSCT from alternative donors including unre-
lated cord, mismatch family, and match unrelated donors.
Only 2 match sibling (11.7%) and one match related (5.9%)
were used as donors. Median follow-up time was 7.05 years
(range 1.82-19.99).
Two patients (11.7%) died 1 month and 2.1 years post HSCT
due to CMV interstitial pneumonitis and severe Streptococcus
pneumoniae sepsis, respectively. Overall survival (OS) at 2-
year was 87.4%. HLA mismatch and stem cell source were not
signiﬁcant factors for OS (p¼ 0.325 and 0.886, consecutively).
In multivariate analysis, age at HSCT, HLA mismatch, and
stem cell sources were also not signiﬁcant.
Five patients (29.4%) developed acute GVHD grade II-IV. The
incidence of acute GVHD (grade II-IV) was higher when using
bone marrow as a stem cell source (p¼ 0.029). Eight (47.1%)
and three patients (17.6%) developed limited and extensive
GVHD. The incidence of chronic GVHD did not differ by age at
HSCT, HLA mismatch, and stem cell source.
Mixed donor chimerism was temporarily observed in 4 pa-
tients (23.5%). Immunosuppressant was adjusted without
donor lymphocyte infusion. Donor chimerism was subse-
quently improved.
We observed chronic GVHD-independent autoimmune
thrombocytopenia in 4 patients (23.5%). One of those four
also developed warm and cold agglutinin positive autoim-
mune hemolytic anemia. All episodes of autoimmune
thrombocytopenia occurred in patients who received cord
blood transplantation. Mixed donor chimerismwas observed
in 3 of those 4 patients who had persistent thrombocyto-
penia. Only one patient who developed autoimmune
thrombocytopenia and hemolytic anemia received treatment
of plasmapheresis and rituximab. This patient eventually
required regular intravenous immunoglobulin infusion due
to persistent hypogammaglobulinemia. Thrombocytopenia
was gradually subsided with the improvement of donor
chimerism in all patients. No malignancy occurred post-
HSCT in this retrospective cohort.
We report an excellent result using a majority of unmanip-
ulated unrelated and mismatched family donors in this
study. Cytopenias were observed in conjunction with utili-
zation of cord blood stem cells and mixed donor chimerism.357
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Introduction: Reduced intensity conditioning (RIC) allows
older patients and those with comorbidities to undergo
